Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity

• US 5,843,979 A
• Filed: 02/12/1996
• Issued: 12/01/1998
• Est. Priority Date: 02/25/1993
• Status: Expired due to Fees

• Current Assignee: Bristol-Myers Squibb Company
• Original Assignee: Bristol-Myers Squibb Company
• Inventors: Kydonieus, Agis F., Wille, John J.
• Primary Examiner(s): FAY, ZOHREH A
• Application Number:
  US08/598,627
• Time in Patent Office: 1,023 Days
• Field of Search: 514/408, 514/558
• US Class Current: 514/408
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/415 1,2-Diazoles
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines

Abstract

Methods and compositions for inhibiting or preventing the skin irritating or sensitizing effects of a skin irritating or sensitizing component of a dermal or transdermal drug delivery system are disclosed. The composition comprises a mast cell degranulating agent which is capable of inducing a state of immunological tolerance to the skin sensitizing agent by delivery prior to, or at the onset of transdermal drug delivery. Such an agent, preferably cis-urocanic acid or an analogue or metabolite thereof, can be administered before, during or after each transdermal drug delivery to achieve immune tolerance countersensitization. Alternatively, the agent can be used to induce countersensitization. The agent is preferably capable of permeating the epidermis and is administered transdermally. Novel methods and compositions comprising cis-urocanic acid or an analogue or metabolite thereof to obtain anti-inflammatory effects are also disclosed.

Claims

1. A method for inducing immunological tolerance in a subject to a skin sensitizing drug or agent administered to the skin, which method comprises administering to said subject prior to, at the onset of, or both prior to and at the onset of, dermal or transdermal delivery of said sensitizing drug or agent, an effective amount of at least one mast cell degranulating agent.

2. A method according to claim 1, wherein said skin sensitizing drug or agent is a transdermally delivered therapeutic drug, a skin permeation enhancing substance, an excipient or a combination thereof.

3. A method according to claim 1, wherein said at least one mast cell degranulating agent is selected from the group consisting of cis-urocanic acid or an analogue or a metabolite thereof;

chloroquine;

capsaicin;

morphine sulfate;

a sodium channel ionophore;

a calcium channel ionophore;

an inhibitor of Na⁺ /K⁺ channel ATPase;

quinine;

4-aminopyridine;

an anti-human IgE antibody;

compound 48/80;

substance P;

estradiol;

somatostatin;

clonidine;

progesterone;

carbachol; and

spantide.

4. A method according to claim 3 wherein said at least one mast cell degranulating agent is cis-urocanic acid, or an analogue or a metabolite thereof.

5. A method according to claim 4 wherein said cis-urocanic acid analogue is selected from the group consisting of a cis or trans isomer of 1-furanacrylic acid, a cis or trans isomer of 2-pyrrole acrylic acid, a cis or trans isomer of 2-thiopheneacrylic acid, and dihydrourocanic acid.

6. A method according to claim 4 wherein said cis-urocanic acid metabolite is selected from the group consisting of histamine, N¹ -methylhistamine, N¹ -methylhistidine, histidine, imidazolepyruvic acid, N³ -methylhistidine, imidazoleacetic acid, hydantoin 5-propionic acid, and imidazolonepropionic acid.

15. A method according to claim 1, 7 or 9, wherein said drug is selected from the group consisting of an angiotensin converting enzyme inhibitor;

a beta adrenergic receptor blocker;

an anti-hypertensive drug other than an angiotensin converting enzyme inhibitor or a beta adrenergic receptor blocker;

an anti-histamine;

an anti-asthmatic drug;

a non-steroidal anti-inflammatory drug;

a central nervous system active drug;

a weight control drug;

an anticoagulant;

a potassium control drug;

an immunomodulatory drug; and

a decongestant.

7. A method for preventing or inhibiting the skin irritating or skin sensitizing effect of a drug administered to the skin, which method comprises administering before, together with, before and together with, or after said drug, an effective amount of at least one mast cell degranulating agent.

8. A method for preventing or inhibiting the skin irritating or skin sensitizing effect of a component of a dermal or transdermal drug delivery system, which method comprises administering before, together with, before and together with, or after said component, an effective amount of at least one mast cell degranulating agent.

9. A method according to claim 8, wherein said component of the transdermal delivery system is a transdermally delivered therapeutic drug, a skin permeation enhancing substance, an excipient or a combination thereof.

10. A method according to claim 8, wherein said at least one mast cell degranulating agent is transdermally administered together with said component.

11. A method according to any one of claims 7-10, wherein said at least one mast cell degranulating agent is selected from the group consisting of cis-urocanic acid or an analogue or a metabolite thereof;

chloroquine;

capsaicin;

morphine sulfate;

a sodium channel ionophore;

a calcium channel ionophore;

an inhibitor of Na⁺ /K⁺ channel ATPase;

quinine;

4-aminopyridine;

an anti-human IgE antibody;

compound 48/80;

substance P;

estradiol;

somatostatin;

clonidine;

progesterone;

carbachol; and

spantide.

12. A method according to claim 11, wherein said at least one mast cell degranulating agent is cis-urocanic acid, or an analogue or a metabolite thereof.

13. A method according to claim 12, wherein said cis-urocanic acid analogue is selected from the group consisting of a cis or trans isomer of 1-furanacrylic acid, a cis or trans isomer of 2-pyrrole acrylic acid, a cis or trans isomer of 2-thiopheneacrylic acid, and dihydrourocanic acid.

14. A method according to claim 12, wherein said cis-urocanic acid metabolite is selected from the group consisting of histamine, N¹ -methylhistamine, N¹ -methylhistidine, histidine, imidazolepyruvic acid, N³ -methylhistidine, imidazoleacetic acid, hydantoin 5-propionic acid, and imidazolonepropionic acid.

16. A method according to claim 8, wherein said component is a skin permeation enhancing substance.

17. A method according to claim 16, wherein said skin permeation enhancing substance is selected from the group consisting of ethanol, oleic acid, oleyl alcohol, linoleic acid, propylene glycol, lauramidopropyl betaine, dimethylsulfoxide, dimethylformamide, decylmethylsulfoxide, N-methylpyrrolidone, isopropyl alcohol,t-butanol and sodium lauryl sulfate.

18. An article useful for preventing or inhibiting the skin irritating or skin sensitizing effect of a component of a dermal or transdermal drug delivery system, said article comprising:

(a) a dermal or transdermal delivery system comprising a therapeutic drug of interest; and

(b) an effective amount of at least one mast cell degranulating agent.

19. An article according to claim 18, wherein said mast cell degranulating agent is included in the transdermal delivery system (a).

20. An article according to claim 18 wherein said at least one mast cell degranulating agent is selected from the group consisting of cis-urocanic acid or an analogue or a metabolite thereof;

chloroquine;

capsaicin;

morphine sulfate;

a sodium channel ionophore;

a calcium channel ionophore;

an inhibitor of Na⁺ /K⁺ channel ATPase;

quinine;

4-aminopyridine;

an anti-human IgE antibody;

compound 48/80;

substance P;

estradiol;

somatostatin;

clonidine;

progesterone;

carbachol; and

spantide.

21. An article according to claim 20 wherein said at least one mast cell degranulating agent is cis-urocanic acid, or an analogue or a metabolite thereof.

22. An article according to claim 18, wherein said drug of interest is selected from the group consisting of an angiotensin converting enzyme inhibitor;

a beta adrenergic receptor blocker;

an anti-hypertensive drug other than an angiotensin converting enzyme inhibitor or a beta adrenergic receptor blocker;

an anti-histamine;

an anti-asthmatic drug;

a non-steroidal anti-inflammatory drug;

a central nervous system active drug;

a weight control drug;

an anticoagulant;

a potassium control drug; and

a decongestant.

23. An article according to claim 18, wherein the transdermal delivery system (a) further comprises a skin permeation enhancing substance.

24. An article according to claim 23, wherein said skin permeation enhancing substance is selected from the group consisting of ethanol, oleic acid, oleyl alcohol, linoleic acid, propylene glycol, lauramidopropyl betaine, dimethylsulfoxide, dimethylformamide, decylmethylsulfoxide, N-methylpyrrolidone, isopropyl alcohol,t-butanol, and sodium lauryl sulfate.

25. A pharmaceutical composition useful for preventing or inhibiting the skin irritating or skin sensitizing effect of a component of a dermal or transdermal drug delivery system, said composition comprising:

an amount of at least one mast cell degranulating agent effective to prevent or inhibit the skin irritating or skin sensitizing effect of a component of a dermal or transdermal drug delivery system and an acceptable pharmaceutical carrier.

26. A pharmaceutical composition according to claim 25, wherein said at least one mast cell degranulating agent is cis-urocanic acid, or an analogue or a metabolite thereof.

27. A pharmaceutical composition according to claim 26, wherein the cis-urocanic acid analogue is selected from the group consisting of a cis or trans isomer of 1-furanacrylic acid, a cis or trans isomer of 2-pyrrole acrylic acid, a cis or trans isomer of 2-thiopheneacrylic acid, and dihydrourocanic acid.

28. A pharmaceutical composition according to claim 26, wherein the cis-urocanic acid metabolite is selected from the group consisting of histamine, N¹ -methylhistamine, N¹ -methylhistidine, histidine, imidazolepyruvic acid, N² -methylhistidine, imidazoleacetic acid, hydantoin 5-propionic acid, and imidazolonepropionic acid.

29. A pharmaceutical composition according to claim 25, wherein the said at least one mast cell degranulating agent is in a form for dermal or transdermal administration.

30. A method for inhibiting an inflammatory reaction in the skin of a subject associated with a skin sensitizing reaction, which method comprises administering to said subject an effective amount of at least one mast cell degranulating agent.

31. A method according to claim 30, wherein said at least one mast cell degranulating agent is selected from the group consisting of cis-urocanic acid or an analogue or a metabolite thereof;

chloroquine;

capsaicin;

morphine sulfate;

a sodium channel ionophore;

a calcium channel ionophore;

an inhibitor of Na⁺ /K⁺ channel ATPase;

quinine;

4-aminopyridine;

an anti-human IgE antibody;

compound 48/80;

substance P;

estradiol;

somatostatin;

clonidine;

progesterone;

carbachol; and

spantide.